Renaissance Technologies LLC increased its stake in Atrion Co. (NASDAQ:ATRI) by 2.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 60,900 shares of the medical instruments supplier’s stock after buying an additional 1,600 shares during the quarter. Renaissance Technologies LLC owned about 3.28% of Atrion worth $51,932,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Kayne Anderson Rudnick Investment Management LLC raised its position in Atrion by 41.6% in the 1st quarter. Kayne Anderson Rudnick Investment Management LLC now owns 132,363 shares of the medical instruments supplier’s stock worth $116,305,000 after purchasing an additional 38,912 shares during the period. Atria Investments LLC purchased a new stake in shares of Atrion in the second quarter worth approximately $2,594,000. First Trust Advisors LP lifted its stake in shares of Atrion by 63.3% during the 2nd quarter. First Trust Advisors LP now owns 6,496 shares of the medical instruments supplier’s stock worth $5,539,000 after acquiring an additional 2,517 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in shares of Atrion by 137.3% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,719 shares of the medical instruments supplier’s stock worth $3,170,000 after acquiring an additional 2,152 shares during the last quarter. Finally, Ontario Teachers Pension Plan Board purchased a new position in Atrion during the 2nd quarter valued at $963,000. 64.69% of the stock is owned by institutional investors.

ATRI stock traded down $0.65 during trading on Wednesday, hitting $765.80. The company had a trading volume of 394 shares, compared to its average volume of 13,111. The firm has a market capitalization of $1.41 billion, a P/E ratio of 39.11 and a beta of 0.22. Atrion Co. has a 52-week low of $624.00 and a 52-week high of $948.03. The company has a 50 day simple moving average of $761.08 and a 200-day simple moving average of $831.04.

Atrion (NASDAQ:ATRI) last announced its quarterly earnings data on Wednesday, August 7th. The medical instruments supplier reported $5.18 earnings per share for the quarter. The company had revenue of $40.10 million during the quarter. Atrion had a net margin of 23.14% and a return on equity of 16.79%.

The business also recently announced a quarterly dividend, which will be paid on Monday, September 30th. Stockholders of record on Monday, September 16th will be given a dividend of $1.55 per share. The ex-dividend date of this dividend is Friday, September 13th. This is a positive change from Atrion’s previous quarterly dividend of $1.35. This represents a $6.20 dividend on an annualized basis and a dividend yield of 0.81%.

ATRI has been the topic of several research analyst reports. ValuEngine downgraded Atrion from a “buy” rating to a “hold” rating in a research report on Friday, July 26th. BidaskClub lowered Atrion from a “sell” rating to a “strong sell” rating in a research note on Wednesday.

Atrion Profile

Atrion Corporation develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications worldwide. Its fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.

Further Reading: What is Liquidity?

Institutional Ownership by Quarter for Atrion (NASDAQ:ATRI)

Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with MarketBeat.com's FREE daily email newsletter.